PG11047: Completed Phase Ib enrollment

Progen completed enrollment of 172 patients in an open-label, dose-escalation, U.S. Phase Ib trial evaluating PG11047 in combination with 1 of 7 cancer drugs. The drugs include Gemzar gemcitabine fro...